Impact BioMedical, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Impact BioMedical, INC. (IBO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-07
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$700.00K.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$2.28M.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $5.24M.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$1.48M, a 134.78% decline year-over-year.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$11.87M.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$24.77M.
- Impact BioMedical, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$4.41M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$700.00K 10-Q · filed 2026-08-07 | -$2.98M 10-Q · filed 2026-08-07 | $2.25M derived: sum of 3 quarters · filed 2026-08-07 | $776.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$2.28M 10-Q · filed 2026-05-12 | $2.95M derived: sum of 2 quarters · filed 2026-05-12 | $1.48M derived: sum of 3 quarters · filed 2026-05-12 | -$12.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.76M derived: sum of 2 quarters · filed 2026-03-11 | -$10.59M derived: sum of 3 quarters · filed 2026-08-07 | -$11.87M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$1.48M 10-Q · filed 2025-11-07 | -$15.83M derived: sum of 2 quarters · filed 2026-08-07 | -$17.11M 10-Q · filed 2025-11-07 | -$44.24M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$14.35M 10-Q · filed 2026-08-07 | -$15.63M 10-Q · filed 2026-08-07 | -$42.76M derived: sum of 3 quarters · filed 2026-08-07 | -$38.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$1.28M 10-Q · filed 2026-05-12 | -$28.41M derived: sum of 2 quarters · filed 2026-05-12 | -$24.17M derived: sum of 3 quarters · filed 2026-05-12 | -$25.05M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$27.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$22.89M derived: sum of 2 quarters · filed 2026-03-11 | -$23.78M derived: sum of 3 quarters · filed 2026-03-11 | -$24.77M 10-K · filed 2026-03-11 |
| 2024-09-30 | $4.24M 10-Q · filed 2025-11-07 | $3.36M derived: sum of 2 quarters · filed 2025-11-07 | $2.36M 10-Q · filed 2025-11-07 | $1.10M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$884.00K 10-Q · filed 2025-08-14 | -$1.88M 10-Q · filed 2025-08-14 | -$3.14M derived: sum of 3 quarters · filed 2025-08-14 | -$4.32M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$998.00K 10-Q · filed 2025-05-14 | -$2.26M derived: sum of 2 quarters · filed 2025-05-14 | -$3.44M derived: sum of 3 quarters · filed 2025-05-14 | -$4.56M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.44M derived: sum of 2 quarters · filed 2025-03-28 | -$3.56M derived: sum of 3 quarters · filed 2025-03-28 | -$4.41M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.18M 10-Q · filed 2024-11-12 | -$2.30M derived: sum of 2 quarters · filed 2024-11-12 | -$3.15M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.12M 10-Q · filed 2024-08-13 | -$1.97M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |